First pharmacophore-based identification of androgen receptor down-regulating agents: discovery of potent anti-prostate cancer agents.

[1]  Z. Hall.  Cancer , 1906, The Hospital.

[2]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[3]  A. Coldman,et al.  Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. , 1990, Cancer research.

[4]  Steven L. Teig,et al.  Chemical Function Queries for 3D Database Search , 1994, J. Chem. Inf. Comput. Sci..

[5]  Andrew Smellie,et al.  Poling: Promoting conformational variation , 1995, J. Comput. Chem..

[6]  P. Sprague.  Automated chemical hypothesis generation and database searching with Catalyst , 1995 .

[7]  C. Young,et al.  A nonsteroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells. , 1999, Endocrinology.

[8]  Shaobo Zhang,et al.  Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells , 2000, Oncogene.

[9]  Y. Chen,et al.  Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. , 2001, Carcinogenesis.

[10]  S. Taneja,et al.  A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone‐refractory prostate carcinoma , 2001, Cancer.

[11]  Chawnshang Chang,et al.  Antitumor agents. 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents. , 2002, Journal of medicinal chemistry.

[12]  E. Messing,et al.  Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Eva M. Krovat,et al.  Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification. , 2003, Journal of medicinal chemistry.

[14]  Chawnshang Chang,et al.  Antitumor agents 222. Synthesis and anti-androgen activity of new diarylheptanoids. , 2003, Bioorganic & medicinal chemistry.

[15]  G. Wilding,et al.  Androgen antagonist activity by the antioxidant moiety of vitamin E, 2,2,5,7,8-pentamethyl-6-chromanol in human prostate carcinoma cells. , 2003, Molecular cancer therapeutics.

[16]  Rolf W Hartmann,et al.  Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy. , 2003, Journal of medicinal chemistry.

[17]  H. Ito,et al.  Androgen receptor involvement in the progression of prostate cancer. , 2003, Endocrine-related cancer.

[18]  Desok Kim,et al.  The Androgen Axis in Recurrent Prostate Cancer , 2004, Clinical Cancer Research.

[19]  M. Blute,et al.  The effects of dietary factors on the androgen receptor and related cellular factors in prostate cancer. , 2004, Current medicinal chemistry.

[20]  Ruth Nussinov,et al.  Predicting molecular interactions in silico: I. A guide to pharmacophore identification and its applications to drug design. , 2004, Current medicinal chemistry.

[21]  J. Wendoloski,et al.  Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening. , 2004, Journal of medicinal chemistry.

[22]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.

[23]  M. Doddareddy,et al.  First pharmacophoric hypothesis for T-type calcium channel blockers. , 2004, Bioorganic & medicinal chemistry.

[24]  D. Tindall,et al.  The androgen receptor: a potential target for therapy of prostate cancer , 2004, Steroids.

[25]  S. Balk,et al.  Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence , 2004, Journal of cellular biochemistry.

[26]  P. Atadja,et al.  Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824 , 2005, Molecular Cancer Therapeutics.

[27]  P. Nelson,et al.  Characterization of Chemical Constituents in Scutellaria baicalensis with Antiandrogenic and Growth-Inhibitory Activities toward Prostate Carcinoma , 2005, Clinical Cancer Research.

[28]  Raj Kumar Gupta,et al.  3D Pharmacophore Model for Insect Repellent Activity and Discovery of New Repellent Candidates , 2005 .

[29]  Pankaj Chopra,et al.  Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. , 2005, Journal of medicinal chemistry.

[30]  Chin‐Chung Wu,et al.  Antitumor agents. 250. Design and synthesis of new curcumin analogues as potential anti-prostate cancer agents. , 2006, Journal of medicinal chemistry.

[31]  A. Bhattacharjee,et al.  Activity of and initial mechanistic studies on a novel antileishmanial agent identified through in silico pharmacophore development and database searching. , 2006, Journal of medicinal chemistry.

[32]  K. Lee,et al.  Antitumor agents 247. New 4-ethoxycarbonylethyl curcumin analogs as potential antiandrogenic agents. , 2006, Bioorganic & medicinal chemistry.

[33]  Cody Schrank,et al.  American Cancer Society , 2005 .